Literature DB >> 22302821

Arrest of myelination and reduced axon growth when Schwann cells lack mTOR.

Diane L Sherman1, Michiel Krols, Lai-Man N Wu, Matthew Grove, Klaus-Armin Nave, Yann-Gaël Gangloff, Peter J Brophy.   

Abstract

In developing peripheral nerves, differentiating Schwann cells sort individual axons from bundles and ensheath them to generate multiple layers of myelin. In recent years, there has been an increased understanding of the extracellular and intracellular factors that initiate and stimulate Schwann cell myelination, together with a growing appreciation of some of the signaling pathways involved. However, our knowledge of how Schwann cell growth is regulated during myelination is still incomplete. The mammalian target of rapamycin (mTOR) is a core kinase in two major complexes, mTORC1 and mTORC2, that regulate cell growth and differentiation in a variety of mammalian cells. Here we show that elimination of mTOR from murine Schwann cells prevented neither radial sorting nor the initiation of myelination. However, normal postnatal growth of myelinating Schwann cells, both radially and longitudinally, was highly retarded. The myelin sheath in the mutant was much thinner than normal; nevertheless, sheath thickness relative to axon diameter (g-ratio) remained constant in both wild-type and mutant nerves from P14 to P90. Although axon diameters were normal in the mutant at the initiation of myelination, further growth as myelination proceeded was retarded, and this was associated with reduced phosphorylation of neurofilaments. Consistent with thinner axonal diameters and internodal lengths, conduction velocities in mutant quadriceps nerves were also reduced. These data establish a critical role for mTOR signaling in both the longitudinal and radial growth of the myelinating Schwann cell.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22302821      PMCID: PMC4298696          DOI: 10.1523/JNEUROSCI.4814-11.2012

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  66 in total

Review 1.  TOR signaling in growth and metabolism.

Authors:  Stephan Wullschleger; Robbie Loewith; Michael N Hall
Journal:  Cell       Date:  2006-02-10       Impact factor: 41.582

2.  Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation.

Authors:  Andrew Y Choo; Sang-Oh Yoon; Sang Gyun Kim; Philippe P Roux; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-27       Impact factor: 11.205

Review 3.  Axonal regulation of myelination by neuregulin 1.

Authors:  Klaus-Armin Nave; James L Salzer
Journal:  Curr Opin Neurobiol       Date:  2006-09-07       Impact factor: 6.627

4.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

Authors:  Dos D Sarbassov; Siraj M Ali; Shomit Sengupta; Joon-Ho Sheen; Peggy P Hsu; Alex F Bagley; Andrew L Markhard; David M Sabatini
Journal:  Mol Cell       Date:  2006-04-06       Impact factor: 17.970

5.  Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy.

Authors:  C Florian Bentzinger; Klaas Romanino; Dimitri Cloëtta; Shuo Lin; Joseph B Mascarenhas; Filippo Oliveri; Jinyu Xia; Emilio Casanova; Céline F Costa; Marijke Brink; Francesco Zorzato; Michael N Hall; Markus A Rüegg
Journal:  Cell Metab       Date:  2008-11       Impact factor: 27.287

6.  Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival.

Authors:  Paul C McDonald; Arusha Oloumi; Julia Mills; Iveta Dobreva; Mykola Maidan; Virginia Gray; Elizabeth D Wederell; Marcel B Bally; Leonard J Foster; Shoukat Dedhar
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

7.  Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.

Authors:  Lynsey Meikle; Kristen Pollizzi; Anna Egnor; Ioannis Kramvis; Heidi Lane; Mustafa Sahin; David J Kwiatkowski
Journal:  J Neurosci       Date:  2008-05-21       Impact factor: 6.167

8.  Constitutively active Akt induces enhanced myelination in the CNS.

Authors:  Ana I Flores; S Priyadarshini Narayanan; Emily N Morse; H Elizabeth Shick; Xinghua Yin; Grahame Kidd; Robin L Avila; Daniel A Kirschner; Wendy B Macklin
Journal:  J Neurosci       Date:  2008-07-09       Impact factor: 6.167

9.  Neurofascins are required to establish axonal domains for saltatory conduction.

Authors:  Diane L Sherman; Steven Tait; Shona Melrose; Richard Johnson; Barbara Zonta; Felipe A Court; Wendy B Macklin; Stephen Meek; Andrew J H Smith; David F Cottrell; Peter J Brophy
Journal:  Neuron       Date:  2005-12-08       Impact factor: 17.173

10.  FAK is required for axonal sorting by Schwann cells.

Authors:  Matthew Grove; Noboru H Komiyama; Klaus-Armin Nave; Seth G Grant; Diane L Sherman; Peter J Brophy
Journal:  J Cell Biol       Date:  2007-01-22       Impact factor: 10.539

View more
  80 in total

1.  Schwann cell-specific deletion of the endosomal PI 3-kinase Vps34 leads to delayed radial sorting of axons, arrested myelination, and abnormal ErbB2-ErbB3 tyrosine kinase signaling.

Authors:  Anne M Logan; Anna E Mammel; Danielle C Robinson; Andrea L Chin; Alec F Condon; Fred L Robinson
Journal:  Glia       Date:  2017-06-15       Impact factor: 7.452

2.  Polyethylene glycol solutions rapidly restore and maintain axonal continuity, neuromuscular structures, and behaviors lost after sciatic nerve transections in female rats.

Authors:  Michelle Mikesh; Cameron L Ghergherehchi; Robert Louis Hastings; Amir Ali; Sina Rahesh; Karthik Jagannath; Dale R Sengelaub; Richard C Trevino; David M Jackson; George D Bittner
Journal:  J Neurosci Res       Date:  2018-04-16       Impact factor: 4.164

3.  Polyethylene glycol treated allografts not tissue matched nor immunosuppressed rapidly repair sciatic nerve gaps, maintain neuromuscular functions, and restore voluntary behaviors in female rats.

Authors:  Michelle Mikesh; Cameron L Ghergherehchi; Sina Rahesh; Karthik Jagannath; Amir Ali; Dale R Sengelaub; Richard C Trevino; David M Jackson; Haley O Tucker; George D Bittner
Journal:  J Neurosci Res       Date:  2018-04-16       Impact factor: 4.164

Review 4.  Schwann cell myelination.

Authors:  James L Salzer
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-06-08       Impact factor: 10.005

5.  YAP/TAZ initiate and maintain Schwann cell myelination.

Authors:  Matthew Grove; Hyukmin Kim; Maryline Santerre; Alexander J Krupka; Seung Baek Han; Jinbin Zhai; Jennifer Y Cho; Raehee Park; Michele Harris; Seonhee Kim; Bassel E Sawaya; Shin H Kang; Mary F Barbe; Seo-Hee Cho; Michel A Lemay; Young-Jin Son
Journal:  Elife       Date:  2017-01-26       Impact factor: 8.140

6.  mTORC1 promotes proliferation of immature Schwann cells and myelin growth of differentiated Schwann cells.

Authors:  Bogdan Beirowski; Keit Men Wong; Elisabetta Babetto; Jeffrey Milbrandt
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-08       Impact factor: 11.205

7.  Expression of oncogenic BRAFV600E in melanocytes induces Schwannian differentiation in vivo.

Authors:  Chi Luo; Jodie R Pietruska; Jinghao Sheng; Roderick T Bronson; Miaofen G Hu; Rutao Cui; Philip W Hinds
Journal:  Pigment Cell Melanoma Res       Date:  2015-06-20       Impact factor: 4.693

Review 8.  mTOR inhibition in epilepsy: rationale and clinical perspectives.

Authors:  Adam P Ostendorf; Michael Wong
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

9.  The TSC1-mTOR-PLK axis regulates the homeostatic switch from Schwann cell proliferation to myelination in a stage-specific manner.

Authors:  Minqing Jiang; Rohit Rao; Jincheng Wang; Jiajia Wang; Lingli Xu; Lai Man Wu; Jonah R Chan; Huimin Wang; Q Richard Lu
Journal:  Glia       Date:  2018-05-03       Impact factor: 7.452

10.  Cholesterol Biosynthesis Supports Myelin Gene Expression and Axon Ensheathment through Modulation of P13K/Akt/mTor Signaling.

Authors:  Emily S Mathews; Bruce Appel
Journal:  J Neurosci       Date:  2016-07-20       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.